The Future of Ob-Gyn Training in the US Post-Dobbs

An estimated 45% of accredited US obstetrics and gynecology residency programs are located in states that currently ban or severely restrict abortions. JAMA Associate Editor Linda Brubaker, MD, and JAMA Internal Medicine Deputy Editor Deborah Grady, MD, speak with medical students, program directors, and other specialists in the ob-gyn training community about new restrictions and their effects on ob-gyn education in the US. Related Content:

• Implications of the Dobbs Decision for Medical Education
• Dobbs Decision Threatens Full Breadth of Ob-Gyn Training
• Medical Indications for Abortion
• Threats to Evidence-Based Care With Teratogenic Medications in States With Abortion Restrictions
• Treating Cancer in Pregnant Patients After Roe v Wade Overturned
• The Challenge of Emergency Abortion Care Following the Dobbs Ruling
• Clinical and Legal Dilemmas of Providing Reproductive Health Care After the Dobbs Decision
• Legal Risks and Ethical Dilemmas for Clinicians in the Aftermath of Dobbs
• The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers
• Reproductive Rights in Neurology—The Supreme Court's Impact on All of Us
• Antiabortion Laws and Implications for Patients With Cardiovascular Disease in Pregnancy

Conflict of Interest Disclosures:

Hannah Nguyen reported that she held leadership positions on Boston University's School of Medicine chapters of SPA-1 and DREAM. Margaux Zimmerman reported that she held leadership positions on Boston University's, School of Medicine chapters of ACOG and DREAM. Dr Gariepy reported that she was the Yale Complex Family Planning fellowship director from 2018 to March 2022, for which she received salary support from her institution; taught undergraduate and medical students, ob-gyn residents, and Complex Family Planning fellows; and is a research mentor for Complex Family Planning fellows who received research grants from the Society of Family Planning Research Fund. Dr Gariepy also reported leadership positions on the board of directors for the Society of Family Planning and the Complex Family Planning Fellowship Council and membership with Physicians for Reproductive Health, the National Abortion Federation, and the Society of Family Planning. Dr Steinauer is a member of the Society of Family Planning. Dr Loder reported that she serves as a principal investigator for contraceptive clinical trials for Merck and Sebela Pharmaceuticals Inc, consults for American Medical Students Association, and serves as program director for Complex Family Planning Fellowship, University of Michigan, Michigan Medicine. No other disclosures were reported.